Contact PI/Project LeaderGERSTENFELD, LOUIS CHARLES
Awardee OrganizationBOSTON CHILDREN'S HOSPITAL
Description
Abstract Text
The overall goal of this proposal is to develop new experimental
strategies to elucidate the functional roles of the bone matrix molecules,
osteocalcin (OC) and bone sialprotein (BSP) during bone tissue growth and
remodeling. We propose (1) to develop transgenic osteoblast cell lines
that constitutively express normal and site-directed mutants of OC and BSP
and (2) to develop in vitro and in vivo procedures to assess the precise
functional roles that OC and BSP play in bone mineralization and
remodeling using these transgenic cells. Experiments have been designed
to critically test the following two hypotheses: that OC provides signals
within the extracellular matrix (ECM) that promote osteoclastogenesis
and/or bone resorption and that BSP provides positional information within
the ECM that is required for osteoblastic and osteoclastic interaction
with the mineralized phase. High efficiency plasmid and retroviral
vectors will be developed for the transfection and selection of avian OC
and BSP genes within specific osteoblastic cell lines. Use of avian genes
offers the unique advantage that sequence differences between the avian
genes and their murine counterparts provides a means to identify with both
molecular and antibody probes the endogenous mouse from the avian gene
products. Structure/function relationships of OC and BSP on extracellular
matrix assembly, mineralization, and osteoblast interaction with, or
response to the ECM will be determined. In vitro studies will focus on
ECM formation and mineralization of the cell lines grown in culture under
mineralizing conditions, while preparative scale levels of the recombinant
mutant proteins will be prepared for screening of their role in promoting
cell adherence and phenotypic effects on cultured osteoclasts and
osteoblasts. Parallel experiments will examine the structure/function
relationships of OC and BSP expression within ECM on osteoclast function
and osteoclastogenesis. Both in vivo and in vitro approaches will be used
in these studies. For the in vivo studies the transgenic cells will be
grown in novel three-dimensional culture devices followed by implantation
into normal syngeneic mice. Histomorphometric parameters will be compared
to determine the effects of the expression of the specific transgenes on
the stoichiometric accumulation of specific ECM proteins and mineral
within the tissue. For studies on remodeling the transgenic tissues which
develop in vivo will be examined by biochemical, histomorphometric, in
situ hybridization, and molecular analysis of osteoclastic development and
functional bone resorption.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
076593722
UEI
Z1L9F1MM1RY3
Project Start Date
01-April-1995
Project End Date
31-March-1999
Budget Start Date
01-April-1995
Budget End Date
31-March-1996
Project Funding Information for 1995
Total Funding
$198,322
Direct Costs
$144,235
Indirect Costs
$54,087
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$198,322
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AR043434-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AR043434-01
Patents
No Patents information available for 1R01AR043434-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AR043434-01
Clinical Studies
No Clinical Studies information available for 1R01AR043434-01
News and More
Related News Releases
No news release information available for 1R01AR043434-01
History
No Historical information available for 1R01AR043434-01
Similar Projects
No Similar Projects information available for 1R01AR043434-01